BridgeBio Pharma, Inc. (BBIO): who owns it and who trades it
As of Nov 16, 2026, BBIO insiders reported 130 open-market sales worth $90.8M and no purchases in the last 12 months, with 93% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil Kumar (CEO), with $48.5M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling BridgeBio Pharma
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Congress mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BBIO
473 funds and institutions reported BBIO shares worth $14.5B at the end of Q2 2026, about 100% of the company. The largest holder is Jupiter Topco LLC with 7.2%.
Funds and institutions (13F) 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 14.11M | 7.20% | $1.1B | – |
| Kohlberg Kravis Roberts & Co. L.P. | 13.26M | 6.77% | $988M | No change |
| Farallon Capital Management, L.l.c. | 10.74M | 5.49% | $800M | +15% |
| BlackRock, Inc. | 10.29M | 5.25% | $766M | -28% |
| Viking Global Investors LP | 9.95M | 5.08% | $741M | -16% |
| Vanguard Capital Management LLC | 7.90M | 4.03% | $588M | +2% |
| Vanguard Portfolio Management LLC | 7.66M | 3.91% | $570M | -5% |
| Wellington Management Group LLP | 5.31M | 2.71% | $395M | +114% |
| Two Sigma Investments, LP | 4.72M | 2.41% | $352M | +51% |
| Aisling Capital Management LP | 4.59M | 2.34% | $342M | -10% |
| State Street Corp | 4.44M | 2.26% | $330M | -10% |
| Citadel Advisors LLC | 3.76M | 1.92% | $280M | +18% |
| Invesco Ltd. | 3.70M | 1.89% | $276M | -19% |
| D. E. Shaw & Co., Inc. | 3.63M | 1.85% | $271M | +43% |
| Geode Capital Management, LLC | 3.42M | 1.75% | $255M | -30% |
| Jane Street Group, LLC | 2.93M | 1.50% | $219M | +67% |
| JPMorgan Chase & Co | 2.40M | 1.22% | $173M | – |
| Adage Capital Partners Gp, L.l.c. | 2.25M | 1.15% | $168M | +276% |
| Franklin Resources Inc | 2.16M | 1.10% | $161M | -11% |
| Polar Capital Holdings Plc | 2.06M | 1.05% | $154M | -18% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BBIO insiders reported $0 of open-market purchases and $90.8M of sales. 93% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Maricel Apuli | Chief Accounting Officer | Sale plan | 2,000 | $72.85 | $146K | Form 4 |
| Sep 17, 2026 | Neil Kumar | CEO | Sale plan | 1,279 | $69.57 | $89K | Form 4 |
| Sep 17, 2026 | Neil Kumar | CEO | Sale plan | 8,721 | $69.01 | $602K | Form 4 |
| Aug 19, 2026 | Neil Kumar | CEO | Sale plan | 100 | $85.65 | $8.6K | Form 4 |
| Aug 19, 2026 | Neil Kumar | CEO | Sale plan | 1,800 | $84.69 | $152K | Form 4 |
| Aug 19, 2026 | Neil Kumar | CEO | Sale plan | 8,100 | $83.86 | $679K | Form 4 |
| Aug 18, 2026 | Neil Kumar | CEO | Sale plan | 14,602 | $82.99 | $1.2M | Form 4 |
| Aug 18, 2026 | Neil Kumar | CEO | Sale plan | 1,900 | $81.15 | $154K | Form 4 |
| Aug 18, 2026 | Neil Kumar | CEO | Sale plan | 17,279 | $82.21 | $1.4M | Form 4 |
| Aug 18, 2026 | Neil Kumar | CEO | Sale plan | 1,199 | $83.77 | $100K | Form 4 |
| Jul 30, 2026 | Maricel Apuli | Chief Accounting Officer | Sale plan | 2,000 | $80.06 | $160K | Form 4 |
| Jul 9, 2026 | Andrea Ellis | Director | Sale plan | 17,167 | $84.00 | $1.4M | Form 4 |
| Jul 9, 2026 | Jennifer E. Cook | Director | Sale plan | 36,167 | $84.00 | $3M | Form 4 |
| Jul 9, 2026 | Jennifer E. Cook | Director | Sale plan | 112,422 | $90.00 | $10.1M | Form 4 |
| Jun 24, 2026 | Jennifer E. Cook | Director | Sale plan | 37,167 | $70.00 | $2.6M | Form 4 |
| Jun 23, 2026 | Jennifer E. Cook | Director | Sale plan | 2,196 | $68.57 | $151K | Form 4 |
| Jun 22, 2026 | Hannah Valantine | Director | Sale plan | 2,808 | $68.00 | $191K | Form 4 |
| Jun 15, 2026 | Jennifer E. Cook | Director | Sale plan | 1,503 | $67.14 | $101K | Form 4 |
| Jun 15, 2026 | Jennifer E. Cook | Director | Sale plan | 88,737 | $66.62 | $5.9M | Form 4 |
| Jun 5, 2026 | Neil Kumar | CEO | Sale plan | 7,147 | $67.20 | $480K | Form 4 |
| Jun 5, 2026 | Neil Kumar | CEO | Sale plan | 4,415 | $68.96 | $304K | Form 4 |
| Jun 5, 2026 | Neil Kumar | CEO | Sale plan | 4,416 | $68.96 | $305K | Form 4 |
| Jun 5, 2026 | Neil Kumar | CEO | Sale plan | 8,437 | $67.88 | $573K | Form 4 |
| Jun 5, 2026 | Neil Kumar | CEO | Sale plan | 7,148 | $67.20 | $480K | Form 4 |
| Jun 4, 2026 | Neil Kumar | CEO | Sale plan | 2,200 | $65.72 | $145K | Form 4 |
| Jun 4, 2026 | Neil Kumar | CEO | Sale plan | 1,429 | $66.72 | $95.3K | Form 4 |
| Jun 4, 2026 | Neil Kumar | CEO | Sale plan | 15,921 | $67.74 | $1.1M | Form 4 |
| Jun 4, 2026 | Neil Kumar | CEO | Sale plan | 450 | $68.27 | $30.7K | Form 4 |
| May 21, 2026 | Neil Kumar | CEO | Sale plan | 800 | $70.92 | $56.7K | Form 4 |
| May 21, 2026 | Neil Kumar | CEO | Sale plan | 2,256 | $67.57 | $152K | Form 4 |
| May 21, 2026 | Neil Kumar | CEO | Sale plan | 6,725 | $68.30 | $459K | Form 4 |
| May 21, 2026 | Neil Kumar | CEO | Sale plan | 5,072 | $69.22 | $351K | Form 4 |
| May 21, 2026 | Neil Kumar | CEO | Sale plan | 11,250 | $70.48 | $793K | Form 4 |
| May 18, 2026 | Thomas Trimarchi | CFO | Sale plan | 10,456 | $64.82 | $678K | Form 4 |
| May 18, 2026 | Thomas Trimarchi | CFO | Sale plan | 3,195 | $65.95 | $211K | Form 4 |
| May 15, 2026 | Randal W. Scott | Director | Sale plan | 200 | $69.12 | $13.8K | Form 4 |
| May 15, 2026 | Randal W. Scott | Director | Sale plan | 2,088 | $67.53 | $141K | Form 4 |
| May 15, 2026 | Randal W. Scott | Director | Sale plan | 1,512 | $68.23 | $103K | Form 4 |
| May 15, 2026 | Randal W. Scott | Director | Sale plan | 6,200 | $66.69 | $413K | Form 4 |
| May 8, 2026 | Neil Kumar | CEO | Sale plan | 13,973 | $66.65 | $931K | Form 4 |
| May 8, 2026 | Neil Kumar | CEO | Sale plan | 5,077 | $67.35 | $342K | Form 4 |
| May 8, 2026 | Neil Kumar | CEO | Sale plan | 950 | $68.35 | $64.9K | Form 4 |
| May 8, 2026 | Neil Kumar | CEO | Sale plan | 13,974 | $66.65 | $931K | Form 4 |
| May 8, 2026 | Neil Kumar | CEO | Sale plan | 5,076 | $67.35 | $342K | Form 4 |
| May 7, 2026 | Neil Kumar | CEO | Sale plan | 8,333 | $68.38 | $570K | Form 4 |
| May 7, 2026 | Neil Kumar | CEO | Sale plan | 450 | $69.09 | $31.1K | Form 4 |
| May 7, 2026 | Neil Kumar | CEO | Sale plan | 11,217 | $67.49 | $757K | Form 4 |
| May 7, 2026 | Neil Kumar | CEO | Sale plan | 8,334 | $68.38 | $570K | Form 4 |
| May 7, 2026 | Neil Kumar | CEO | Sale plan | 11,217 | $67.50 | $757K | Form 4 |
| May 7, 2026 | Neil Kumar | CEO | Sale plan | 449 | $69.09 | $31K | Form 4 |
| Apr 30, 2026 | Maricel Apuli | Chief Accounting Officer | Sale plan | 2,000 | $71.58 | $143K | Form 4 |
| Apr 10, 2026 | Neil Kumar | CEO | Sale plan | 20,000 | $74.60 | $1.5M | Form 4 |
| Apr 9, 2026 | Neil Kumar | CEO | Sale plan | 7,200 | $73.64 | $530K | Form 4 |
| Apr 9, 2026 | Neil Kumar | CEO | Sale plan | 7,800 | $75.53 | $589K | Form 4 |
| Apr 9, 2026 | Neil Kumar | CEO | Sale plan | 5,128 | $74.57 | $382K | Form 4 |
| Apr 9, 2026 | Neil Kumar | CEO | Sale plan | 7,072 | $73.64 | $521K | Form 4 |
| Apr 9, 2026 | Neil Kumar | CEO | Sale plan | 7,500 | $75.55 | $567K | Form 4 |
| Apr 9, 2026 | Neil Kumar | CEO | Sale plan | 5,300 | $74.60 | $395K | Form 4 |
| Mar 13, 2026 | Neil Kumar | CEO | Sale plan | 9,759 | $69.23 | $676K | Form 4 |
| Mar 13, 2026 | Neil Kumar | CEO | Sale plan | 9,690 | $68.36 | $662K | Form 4 |
| Mar 13, 2026 | Neil Kumar | CEO | Sale plan | 10,310 | $69.20 | $713K | Form 4 |
| Mar 13, 2026 | Neil Kumar | CEO | Sale plan | 10,241 | $68.39 | $700K | Form 4 |
| Mar 12, 2026 | Neil Kumar | CEO | Sale plan | 300 | $70.15 | $21K | Form 4 |
| Mar 12, 2026 | Neil Kumar | CEO | Sale plan | 5,815 | $69.29 | $403K | Form 4 |
| Mar 12, 2026 | Neil Kumar | CEO | Sale plan | 5,363 | $69.32 | $372K | Form 4 |
| Mar 12, 2026 | Neil Kumar | CEO | Sale plan | 14,337 | $68.48 | $982K | Form 4 |
| Mar 12, 2026 | Neil Kumar | CEO | Sale plan | 13,885 | $68.47 | $951K | Form 4 |
| Mar 10, 2026 | Hannah Valantine | Director | Sale plan | 8,671 | $72.00 | $624K | Form 4 |
| Mar 4, 2026 | Andrea Ellis | Director | Sale plan | 64,921 | $64.87 | $4.2M | Form 4 |
| Feb 27, 2026 | Hannah Valantine | Director | Sale plan | 10,900 | $67.84 | $739K | Form 4 |
| Feb 27, 2026 | Hannah Valantine | Director | Sale plan | 14,584 | $67.08 | $978K | Form 4 |
| Feb 26, 2026 | Maricel Apuli | Chief Accounting Officer | Sale plan | 2,000 | $66.00 | $132K | Form 4 |
| Feb 19, 2026 | Neil Kumar | CEO | Sale plan | 18,923 | $71.03 | $1.3M | Form 4 |
| Feb 19, 2026 | Neil Kumar | CEO | Sale plan | 8,528 | $72.08 | $615K | Form 4 |
| Feb 19, 2026 | Neil Kumar | CEO | Sale plan | 602 | $72.80 | $43.8K | Form 4 |
| Feb 17, 2026 | Maricel Apuli | Chief Accounting Officer | Sale plan | 510 | $74.31 | $37.9K | Form 4 |
| Feb 17, 2026 | Thomas Trimarchi | CFO | Sale plan | 200 | $75.38 | $15.1K | Form 4 |
| Feb 17, 2026 | Thomas Trimarchi | CFO | Sale plan | 13,400 | $74.71 | $1M | Form 4 |
| Feb 17, 2026 | Randal W. Scott | Director | Sale plan | 1,900 | $74.34 | $141K | Form 4 |
| Feb 17, 2026 | Randal W. Scott | Director | Sale plan | 4,793 | $75.57 | $362K | Form 4 |
| Feb 17, 2026 | Randal W. Scott | Director | Sale plan | 3,307 | $75.93 | $251K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 7,860 | $70.70 | $556K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 3,994 | $73.25 | $293K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 3,961 | $73.25 | $290K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 4,404 | $72.65 | $320K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 3,775 | $71.46 | $270K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 4,484 | $72.64 | $326K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 7,806 | $70.69 | $552K | Form 4 |
| Feb 11, 2026 | Neil Kumar | CEO | Sale plan | 3,716 | $71.44 | $265K | Form 4 |
| Feb 10, 2026 | Neil Kumar | CEO | Sale plan | 5,799 | $72.28 | $419K | Form 4 |
| Feb 10, 2026 | Neil Kumar | CEO | Sale plan | 14,040 | $71.80 | $1M | Form 4 |
| Feb 10, 2026 | Neil Kumar | CEO | Sale plan | 5,960 | $72.27 | $431K | Form 4 |
| Feb 10, 2026 | Neil Kumar | CEO | Sale plan | 14,201 | $71.80 | $1M | Form 4 |
| Jan 9, 2026 | Neil Kumar | CEO | Sale plan | 2,151 | $75.75 | $163K | Form 4 |
| Jan 9, 2026 | Neil Kumar | CEO | Sale plan | 1,855 | $78.10 | $145K | Form 4 |
| Jan 9, 2026 | Neil Kumar | CEO | Sale plan | 10,677 | $77.46 | $827K | Form 4 |
| Jan 9, 2026 | Neil Kumar | CEO | Sale plan | 6,067 | $76.53 | $464K | Form 4 |
| Jan 9, 2026 | Neil Kumar | CEO | Sale plan | 1,401 | $75.61 | $106K | Form 4 |
| Jan 9, 2026 | Neil Kumar | CEO | Sale plan | 375 | $78.19 | $29.3K | Form 4 |
| Jan 9, 2026 | Neil Kumar | CEO | Sale plan | 10,519 | $77.61 | $816K | Form 4 |
Latest 100 of 130 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Neil Kumar | Chief Executive Officer, Director | – | $48.5M | Sep 17, 2026 |
| Jennifer E. Cook | Director | – | $21.9M | Jul 9, 2026 |
| Andrew Lo | Director | – | $6.3M | Nov 18, 2025 |
| Andrea Ellis | Director | – | $5.7M | Jul 9, 2026 |
| Thomas Trimarchi | President and CFO | – | $3M | May 18, 2026 |
| Hannah Valantine | Director | – | $2.5M | Jun 22, 2026 |
| Randal W. Scott | Director | – | $2.1M | May 15, 2026 |
| Maricel Apuli | Chief Accounting Officer | – | $767K | Oct 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BBIO short interest
High short interest. 10.7% of BBIO shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 14%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 20.85M BBIO shares were sold short, 10.7% of the shares outstanding, up 4.2% from the report before. At the average daily volume of 2.95M shares, buying them all back would take about 7.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 20.85M | 10.70% | +4% | 2.95M | 7.1 |
| Oct 15, 2026 | 20.00M | 10.23% | +2% | 2.60M | 7.7 |
| Sep 30, 2026 | 19.67M | 10.06% | -9% | 3.36M | 5.8 |
| Sep 15, 2026 | 21.55M | 11.02% | -1% | 2.04M | 10.5 |
| Aug 31, 2026 | 21.85M | 11.18% | -6% | 1.95M | 11.2 |
| Aug 14, 2026 | 23.32M | 11.93% | -0% | 2.16M | 10.8 |
| Jul 31, 2026 | 23.34M | 11.92% | -9% | 2.03M | 11.5 |
| Jul 15, 2026 | 25.75M | 13.15% | +7% | 4.79M | 5.4 |
| Jun 30, 2026 | 24.10M | 12.31% | -5% | 5.34M | 4.5 |
| Jun 15, 2026 | 25.42M | 12.98% | +4% | 2.97M | 8.6 |
| May 29, 2026 | 24.39M | 12.45% | +1% | 2.54M | 9.6 |
| May 15, 2026 | 24.16M | 12.34% | +1% | 2.77M | 8.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded BBIO
Since Nov 17, 2024, 1 member of Congress reported 9 purchases and 1 sale of BBIO. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Nov 2, 2026, reported Nov 10, 2026.
Purchases 9Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Nov 10, 2026 | Report |
| Oct 27, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Nov 10, 2026 | Report |
| Sep 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Oct 12, 2026 | Report |
| May 11, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| Apr 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 8, 2026 | Report |
| Mar 19, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Mar 18, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Sep 22, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Oct 10, 2025 | Report |
| Aug 8, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 12, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
BridgeBio Pharma company events
BridgeBio Pharma filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Oct 13, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by… Filing
- Aug 31, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled, “BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein… Filing
- Aug 17, 2026AgreementBridgeBio Pharma, Inc. and KKR Genetic Disorder L.P. entered into an Underwriting Agreement with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as the representatives of the several underwriters listed on Schedule I thereto, related to an offering of 5,000,000… Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 22, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
- Jul 2, 2026AgreementBridgeBio Pharma, Inc. entered into an Investment Agreement with the purchasers identified therein, including Chinotto Investments, LLC and HCRx Investments HoldCo, L.P., providing for the issuance and sale by the Company to the Purchasers of shares of the Company’s Series A Cumulative Convertible… Filing
- Jun 26, 2026LeadershipDr. Randal W. Scott notified BridgeBio Pharma, Inc., of his resignation as a member of the Board of Directors of the Company upon the completion of his term as a Class I director, effective as of June 22, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders. Filing
- May 27, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
- May 13, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
- May 8, 2026AgreementBridgeBio Pharma, Inc. filed a registration statement on Form S-3ASR (File No.: 333-295678, the “Registration Statement”) under Rule 415 of the Securities Act of 1933, as amended with the Securities and Exchange Commission . In addition, on May 7, 2026, the Company entered into an Equity… Filing
- May 7, 2026AnnouncementThe Board of Directors of the Company approved a stock repurchase program pursuant to which the Company may purchase up to $500 million of the Company’s outstanding common stock. Filing
- Mar 30, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Feb 12, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia.” A copy of the press release is attached as Exhibit 99.1 to this Current… Filing
- Jan 21, 2026AgreementBridgeBio Pharma, Inc. issued an aggregate of $632.5 million of its 0.75% Convertible Senior Notes due 2033, pursuant to an Indenture dated January 21, 2026, between BridgeBio and U.S. Bank Trust Company, National Association, as trustee, in a private offering to qualified institutional buyers… Filing
- Jan 12, 2026AnnouncementThe Company also presented a business update at the 44 th Annual J.P. Morgan Healthcare Conference. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
BridgeBio Pharma financials
Famous investors that hold BBIO
7 of the 50 well-known investors we track reported holding BBIO in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $644M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 9.79M | $644M | 2.0% | -2% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.73M | $114M | 0.1% | -54% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 856,546 | $56.4M | 0.1% | No change |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 695,638 | $45.8M | 0.2% | +55% |
| Israel Englander · Millennium Management | Q3 2026 | 622,296 | $40.9M | 0.0% | +28% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 602,374 | $39.6M | 0.1% | -61% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 348,675 | $22.9M | 0.0% | +1% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 12, 2026 | Farallon Capital Management, L.L.C. | 13G/A | 7.3% |
| Nov 12, 2026 | Farallon Capital Management, L.L.C. | 13G/A | 7.3% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.1% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.1% |
Questions about BridgeBio Pharma, Inc. (BBIO) stock
Who owns the most BBIO stock?
The largest reported owner of BridgeBio Pharma, Inc. (BBIO) is Jupiter Topco LLC, with 7.2% of the company. In total, 473 funds and institutions reported holding BBIO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BBIO insiders buying or selling?
In the last 12 months, BBIO insiders reported no open-market purchases and 130 sales worth $90.8M. The latest trade was on Oct 30, 2026. See every trade.
What is the short interest in BBIO?
As of Oct 30, 2026, 20.85M BBIO shares were sold short, 10.7% of the shares outstanding, up 4.2% from the report before. At the average daily volume of 2.95M shares, buying them all back would take about 7.1 trading days (days to cover). See the history.
Have members of Congress traded BBIO?
Yes. 1 member of Congress reported 9 purchases and 1 sale of BBIO since Nov 17, 2024. The latest was reported on Nov 10, 2026. See the trades.
Which famous investors hold BBIO?
7 of the 50 well-known investors we track reported BBIO in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Jim Simons. The largest position is worth $644M. See all holders.
Executive pay
BridgeBio Pharma's chief executive was paid a total of $14.9M for the year ended Dec 31, 2025, down 4% from $15.6M the year before. In the last 12 months, BridgeBio Pharma's executives and directors bought no stock on the open market and sold $90.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.